Intraocular pressure changes in the vitreon study.
OBJECTIVE
To detect the effect of Perfluoroperhydrophenanthrene (vitreon) on intraocular pressure (IOP) changes.


METHODS
One hundred-five eyes with proliferative vitreoretinopathy undergoing vitrectomy using vitreon as an intraoperative surgical adjunct were randomized to 2 groups. Vitreon was completely removed in 43 eyes (Group A) at the end of operation while it was left intravitreally in 62 eyes (Group B) for 4 weeks. Patients were followed for at least 18 months.


RESULTS
During the first postoperative week, 6 eyes (14%) in Group A and 14 eyes (22%) in Group B had IOP of 23 mm Hg or more (P = .393) while no eyes in either group had hypotony. At the last follow-up 2 eyes (5%) in Group A and 6 eyes (10%) in Group B showed chronic hypotony (P = .561).


CONCLUSIONS
Although postoperative chronic hypotony risk increased twofold by vitreon when it was left intravitreally for 4 weeks, this difference was statistically insignificant. Vitreon can be used as a vitreous substitute for 4 weeks in this regard.
Batman
C
C
Department of Vitreoretinal Surgery, SSK Eye Hospital, Ankara, Turkey.
Cekiç
O
O
Totan
Y
Y
Aslan
O
O
Ozalp
S
S
D000328:Adult; D000368:Aged; D005260:Female; D005466:Fluorocarbons / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D015814:Ocular Hypotension / Q000139:chemically induced / Q000503:physiopathology; D011379:Prognosis; D012307:Risk Factors; D014821:Vitrectomy / Q000379:methods*; D018630:Vitreoretinopathy, Proliferative / Q000503:physiopathology / Q000601:surgery*; D014822:Vitreous Body
D005466:Fluorocarbons; C047722:perfluorophenanthrene